Vijay Viswanathan 1, Udyama Juttada 1, Mary Babu
Main idea: Early and regular application of the human epidermal growth factor on diabetic foot ulcers will lead to prevention of leg amputations and would serve to act as a major treatment therapy for healing of chronic wounds.
To validate the efficacy of recombinant human epidermal growth factor (hEGH) in healing diabetic foot ulcers (DFUs) at biochemical and molecular levels. 50 noninfected DFU subjects were recruited for the study and divided into 2 groups based on the treatment applied to the subjects. Patients were observed for 30 days and punch biopsy was taken on days 0 and 14. Collagen and fibroblasts were significantly developed in group 1 when observed in the follow-up samples. The healing time of the wound among the group 1 subjects was significantly less than the group 2 subjects and they even showed a better blood glucose level after 30 days.